Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study.

Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study. Abstract Text:

Robert M Mentzer,Claus Bartels,Roberto Bolli,Steven Boyce,Gerald D Buckberg,Bernard Chaitman,Axel Haverich,John Knight,Philippe ,M Lee Myers,Jose Nicolau,Maarten Simoons,Lars Thulin,Richard D Weisel, ,

BACKGROUND: The EXPEDITION study addressed the efficacy and safety of inhibiting the sodium hydrogen exchanger isoform-1 (NHE-1) by cariporide in the prevention of death or myocardial infarction (MI) in patients undergoing coronary artery bypass graft surgery. The premise was that inhibition of NHE-1 limits intracellcular Na accumulation and thereby limits Na/Ca-exchanger-mediated calcium overload to reduce infarct size. METHODS: High-risk coronary artery bypass graft surgery patients (n = 5,761) were randomly allocated to receive either intravenous cariporide (180 mg in a 1-hour preoperative loading dose, then 40 mg per hour over 24 hours and 20 mg per hour over the subsequent 24 hours) or placebo. The primary composite endpoint of death or MI was assessed at 5 days, and patients were followed for as long as 6 months. RESULTS: At 5 days, the incidence of death or MI was reduced from 20.3% in the placebo group to 16.6% in the treatment group (p = 0.0002). Paradoxically, MI alone declined from 18.9% in the placebo group to 14.4% in the treatment group (p = 0.000005), while mortality alone increased from 1.5% in the placebo group to 2.2% with cariporide (p = 0.02). The increase in mortality was associated with an increase in cerebrovascular events. Unlike the salutary effects that were maintained at 6 months, the difference in mortality at 6 months was not significant. CONCLUSIONS: The EXPEDITION study is the first phase III myocardial protection trial in which the primary endpoint was achieved and proof of concept demonstrated. As a result of increased mortality associated with an increase in cerebrovascular events, it is unlikely that cariporide will be used clinically. The findings suggest that sodium hydrogen exchanger isoform-1 inhibition holds promise for a new class of drugs that could significantly reduce myocardial injury associated with ischemia-reperfusion injury.

Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study. Publishing Authors By Initials

RM Mentzer,C Bartels,R Bolli,S Boyce,GD Buckberg,B Chaitman,A Haverich,J Knight,P ,ML Myers,J Nicolau,M Simoons,L Thulin,RD Weisel, ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Annals of thoracic surgery

VOLUME: 85

Page Numbers: 1261-70

Journal Abbreviation: Ann. Thorac. Surg.

ISSN: 1552-6259

DAY: 21

MONTH: Apr

YEAR: 2008

Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 15030100

Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study.

AFFILIATION:

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ann Thorac Surg

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study Related Publications

• Biophysics. Enigmas of blood clot elasticity.
• Calcium channel blockers in myocardial and cerebral ischemia: a clinician's review from bench to bedside.
• Cell transplantation: back to the bench: introduction.
• Choroidal detachment in the surgical treatment of retinal separation.
• Direct evidence for specific interactions of the fibrinogen alphaC-domains with the central E region and with each other.
• Dynamic imaging of fibrin network formation correlated with other measures of polymerization.
• Fibrinogen Guarenas, an abnormal fibrinogen with an Aalpha-chain truncation due to a nonsense mutation at Aalpha 467 Glu (GAA)-->stop (TAA).
• Forced Unfolding of Coiled-Coils in Fibrinogen by Single-Molecule AFM.
• Future directions of vitamin E and its analogues in minimizing myocardial ischemia-reperfusion injury.
• Glycaemic control improves fibrin network characteristics in type 2 diabetes - A purified fibrinogen model.
• Haemostatic changes related to fibrin formation and fibrinolysis during the first trimester in normal pregnancy and in recurrent miscarriage.
• Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release.
• Interactions mediated by the N-terminus of fibrinogen's Bbeta chain.
• Passive dosimeters for nitrogen dioxide in personal/indoor air sampling: a review.
• Polymerization of fibrin: Direct observation and quantification of individual B:b knob-hole interactions.
• Relation of salinity to the activity of the spermatozoa of Gillichthys, a marine teleost.
• Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study.
• Structure of fibrin: impact on clot stability.
• Which knobs fit into which holes in fibrin polymerization?